Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.

Author(s): Von Hoff DD, Fleming TR, Macdonald JS, Goodman PJ, Van Damme J, Brown TD, O'Rourke T, Feun LG, Keppen MD

Affiliation(s): University of Texas Health Science Center, San Antonio 78284-7884.

Publication date & source: 1990-12, J Biol Response Mod., 9(6):584-7.

Publication type: Clinical Trial; Randomized Controlled Trial

Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant gamma-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. gamma-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.